MX2022015757A - Compuestos de union a cereblon, composiciones de los mismos y metodos de tratamiento con estos. - Google Patents

Compuestos de union a cereblon, composiciones de los mismos y metodos de tratamiento con estos.

Info

Publication number
MX2022015757A
MX2022015757A MX2022015757A MX2022015757A MX2022015757A MX 2022015757 A MX2022015757 A MX 2022015757A MX 2022015757 A MX2022015757 A MX 2022015757A MX 2022015757 A MX2022015757 A MX 2022015757A MX 2022015757 A MX2022015757 A MX 2022015757A
Authority
MX
Mexico
Prior art keywords
sup
compositions
methods
binding compounds
treatment therewith
Prior art date
Application number
MX2022015757A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Norris
Lida Tehrani
Joshua Hansen
Dehua Huang
Matthew D Correa
Brandon W Whitefield
Virginia Heather Sharron Grant
Veronique Plantevin-Krenitsky
Matthew D Alexander
Evan J Horn
Christopher Mayne
John J Sapienza
Deepak Dalvie
Iii Roy L Harris
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022015757A publication Critical patent/MX2022015757A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2022015757A 2020-06-24 2021-06-23 Compuestos de union a cereblon, composiciones de los mismos y metodos de tratamiento con estos. MX2022015757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043555P 2020-06-24 2020-06-24
PCT/US2021/038618 WO2021262810A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
MX2022015757A true MX2022015757A (es) 2023-01-19

Family

ID=79032408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015757A MX2022015757A (es) 2020-06-24 2021-06-23 Compuestos de union a cereblon, composiciones de los mismos y metodos de tratamiento con estos.

Country Status (17)

Country Link
US (3) US11634407B2 (https=)
EP (1) EP4171566A4 (https=)
JP (2) JP7781792B2 (https=)
KR (1) KR20230027066A (https=)
CN (2) CN120441548A (https=)
AR (1) AR122723A1 (https=)
AU (1) AU2021296833A1 (https=)
BR (1) BR112022025933A2 (https=)
CA (1) CA3182325A1 (https=)
CL (1) CL2022003719A1 (https=)
CO (1) CO2022018653A2 (https=)
IL (1) IL299256A (https=)
MX (1) MX2022015757A (https=)
PE (1) PE20231746A1 (https=)
SA (1) SA522441857B1 (https=)
TW (1) TW202216680A (https=)
WO (1) WO2021262810A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
CN117561249A (zh) * 2021-06-25 2024-02-13 细胞基因公司 Cereblon结合化合物、其组合物及其用于治疗的方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN110769822A (zh) * 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2020051260A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Also Published As

Publication number Publication date
AR122723A1 (es) 2022-09-28
US20250188056A1 (en) 2025-06-12
CA3182325A1 (en) 2021-12-30
EP4171566A4 (en) 2024-07-24
SA522441857B1 (ar) 2024-07-21
PE20231746A1 (es) 2023-11-06
US20210403454A1 (en) 2021-12-30
US20230242509A1 (en) 2023-08-03
IL299256A (en) 2023-02-01
US11634407B2 (en) 2023-04-25
JP7781792B2 (ja) 2025-12-08
JP2026035702A (ja) 2026-03-04
WO2021262810A1 (en) 2021-12-30
CN115835866B (zh) 2025-05-02
KR20230027066A (ko) 2023-02-27
AU2021296833A1 (en) 2023-01-19
CL2022003719A1 (es) 2023-05-12
CN120441548A (zh) 2025-08-08
JP2023533203A (ja) 2023-08-02
US12103920B2 (en) 2024-10-01
EP4171566A1 (en) 2023-05-03
CN115835866A (zh) 2023-03-21
TW202216680A (zh) 2022-05-01
CO2022018653A2 (es) 2023-03-27
BR112022025933A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
MX2022015757A (es) Compuestos de union a cereblon, composiciones de los mismos y metodos de tratamiento con estos.
EP4494711A3 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
MX2022011534A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
MX2021007475A (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
MY206796A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
ATE477311T1 (de) Beschichtungszusammensetzung und verfahren
NO20081421L (no) Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
DE60324544D1 (de) Muskarin antagonisten
ZA200202518B (en) Certain alkylene diamine-substituted heterocycles.
MX2021012706A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
WO2005030120A3 (en) Antiangiogenic agents
PL1765816T3 (pl) Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych
TW200719903A (en) Compositions for the treatment of neoplasms
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
ZA202306427B (en) Herbicidal malonamides
MX2024002372A (es) Malonamidas herbicidas.
ATE353886T1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase
MX2024014168A (es) Antagonistas de at2r y usos de estos
EA202191712A1 (ru) Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью
MX2025000919A (es) Derivados biciclicos de tetrahidrotiazepina
WO2023036054A3 (en) Composition and method for treating hemophilia
EA202191713A1 (ru) Замещенные соединения 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью
CY1113828T1 (el) Ενωσεις τριαζολιου που ρυθμιζουν δραστικοτητα hsp90